NCT06211114View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 9, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
Collecting Duct Carcinoma
Interventions
DRUG

PD-(L)1 inhibitor

Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks

DRUG

Axitinib

axitinib 5mg orally twice daily

Trial Locations (2)

100000

RECRUITING

Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing

100086

NOT_YET_RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER